Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC.
Aldred J, et al. Among authors: criswell sr.
Neurol Ther. 2023 Dec;12(6):1959-1960. doi: 10.1007/s40120-023-00554-w.
Neurol Ther. 2023.
PMID: 37817017
Free PMC article.
No abstract available.